Charity number: 1123760 Company number: 6078396
(England and Wales)
British Society for Histocompatibility and Immunogenetics
Report of the Trustees and Unaudited Financial Statements
For the year ended 31 December 2024
British Society for Histocompatibility and Immunogenetics Contents Page For the year ended 31 December 2024
| Report of the Trustees | 1 to 4 |
|---|---|
| Independent Examiner's Report to the Trustees | 5 |
| Statement of Financial Activities | 6 |
| Statement of Financial Position | 7 |
| Notes to the Financial Statements | 8 to 13 |
| Detailed Statement of Financial Activities | 14 to 15 |
British Society for Histocompatibility and Immunogenetics Report of the Trustees
For the year ended 31 December 2024
The Trustees, who are also directors for the purposes of company law, have pleasure in presenting their report and the financial statements for the charitable company for the year ended 31 December 2024. The Trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102) (effective 1 January 2019).
OBJECTIVES AND ACTIVITIES
The objects of the Society, as stated in its Memorandum of Association, are;
To promote and protect health for the public benefit in particular by:
(a) developing and maintaining good practice in Histocompatibility and Immunogenetics by ensuring the highest professional standards of competence;
(b) encouraging the advancement of scientific research and knowledge and of its application in all aspects of Histocompatibility and Immunogenetics and disseminating the useful results thereof.
The main activities of the society that contribute to the achievement of the objectives are;
Annual Conference
BSHI Annual Conference was held in person in 2024.The meeting provided an educational programme of lectures and seminars, including plenary lectures provided by world experts in the field of histocompatibility and Immunogenetics. Sessions were also held for BSHI Members to present short talks and case studies.
Two awards sessions were held. One for best abstract and one session for the Next Generation Scientist.
Objectives and aims
The trustees have considered the Charity Commission's guidance on public benefit, including the guidance 'public benefit: running a charity (PB2)'.
1 of 15
British Society for Histocompatibility and Immunogenetics Report of the Trustees Continued
For the year ended 31 December 2024
ACHIEVEMENTS AND PERFORMANCE
Diploma and other training courses
BSHI supplies and administers a Diploma in Histocompatibility and Immunogenetics, to facilitate specialist learning in the field. Graduating diplomats received their awards at the Annual Conference.
A successful series of one and two day training courses were held to support BSHI Diploma, Trainee Clinical Scientists, Biomedical Scientists and those undertaking higher qualifications.
BSHI ran a higher training meeting for members considering taking the FRC Path examinations.
BSHI also administers a CPD scheme for the membership.
Special Interest Groups
The special interest groups were all busy this year providing educational workshops and forums for discussion between the different laboratories. The 3 active SIGs are the Antibody SIG, the Next Generation Sequencing SIG and the Haematopoietic Stem Cell SIG with meetings held this year around platelets and transplanting highly sensitised patients.
Bursaries and Grants
BSHI supplied bursaries to its members to attend scientific and educational meetings. These included the European Federation of Immunogenetics and British Society for Histocompatibility and Immunogenetics meetings.
The society also awarded the Julia Bodmer Travel Award, which allows a junior member of the society the opportunity to visit another laboratory to bring back some research ideas or new technology to their own laboratory. The recipient of the award presents their findings at the BSHI annual conference.
Representation to other professional bodies
The BSHI has nominated representatives to a number of other professional organisations and these representatives link to the BSHI Committee through the Professional Advisory Group. Elected members of BPAG are responsible for co-ordinating BSHI input to official working groups and documents.
BSHI is represented at the Association of Clinical Scientists, Clinical Pathology Accreditation UK Ltd, the Federation of Healthcare Science, the National External Quality Assurance Advisory Panel for Immunology, and the Royal College of Pathologists and NHSBT-ODT advisor groups.
Establishment and maintenance of appropriate standards within H & I is addressed through the BPAG. BPAG will interact with other professional organisations e.g. European Federation for Immunogenetics, British Transplantation Society as required and set up Standards Working Groups to address specific topics.
Online Virtual Conference Facility
BSHI provides virtual conference infrastructure via Microsoft Teams, enabling remote conferencing and education to take place and at the same time reducing waste and carbon impact.
Online Scientific Journals
BSHI continues to supply access to scientific literature that members do not readily have access to.
Publications
BSHI publishes a quarterly newsletter which is sent to all of the memberships. This contains reports from meetings, CPD journal based learning exercises and updates on developments within the society.
Online CPD Scheme
BSHI provides and manages online Continuing Professional Development, (CPD) scheme for its members via CPDMe.
2 of 15
British Society for Histocompatibility and Immunogenetics Report of the Trustees Continued
For the year ended 31 December 2024
FINANCIAL REVIEW
Reserves
The overall reserves of the charity have again increased to £121,509 which leaves the charity in a strong position to continue to pursue its objectives for the foreseeable future.
Going concern
The trustees are confident that BSHI will be able to continue and pursue its objectives for the foreseeable future.
REFERENCE AND ADMINISTRATIVE INFORMATION
Name of Charity British Society for Histocompatibility and Immunogenetics Charity registration number 1123760 Company registration number 6078396 Principal address C/O Executive Business Support Ltd City Wharf Davidson Road Lichfield Staffs WS14 9DZ
Trustees
The trustees and officers serving during the year and since the year end were as follows:
Richard Battle Daniel Eggleston Corinna Freeman Helena Lee Jessie Martin Sarah Peacock Emily Ryan Olivia Shaw Carla Rosser (Appointed: 23 August 2024) Rachel Smith (Resigned: 31 January 2024) Sarah Maxfield (Appointed: 23 August 2024) Rebecca McGuire (Appointed: 02 February 2024) Raymond Fernando (Appointed: 02 February 2024) Secretary Carla Rosser Independent examiner Marie Hartwell VESEY Accounting Services Ltd Suite 1, Trinity House 33a Market Street Lichfield, Staffs WS13 6LA
3 of 15
British Society for Histocompatibility and Immunogenetics Report of the Trustees Continued
For the year ended 31 December 2024
Bankers
Barclays Bank Plc Witham Business Centre 59 Newland Street Witham Essex CM8 2AJ
Approved by the Board of Trustees and signed on its behalf by
10 September 2025 Corinna Freeman.............................................................................
4 of 15
British Society for Histocompatibility and Immunogenetics Independent Examiners Report to the Trustees
For the year ended 31 December 2024
I report to the trustees on my examination of the accounts of the charitable company for the year ended 31 December 2024.
Responsibilities and basis of report
As the charity Trustees, who are also directors for the purposes of company law, are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').
Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.
Independent examiners qualified statement
I confirm that no other matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:
-
accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
-
the accounts do not accord with those records; or
-
the accounts do not comply with the requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
-
the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).
I confirm that there are no other matters to which your attention should be drawn to enable a proper understanding of the accounts to be reached.
Marie Hartwell VESEY Accounting Services Ltd Suite 1, Trinity House 33a Market Street Lichfield, Staffs WS13 6LA
10 September 2025
5 of 15
British Society for Histocompatibility and Immunogenetics Statement of Financial Activities (including Income and Expenditure Account) For the year ended 31 December 2024
| Notes Income and endowments from: Charitable activities 3 Other trading activities 4 Investments 5 Total Expenditure on: Charitable activities 6/7 Total Net income Reconciliation of funds Total funds brought forward Total funds carried forward |
Unrestricted funds £ 102,368 - 1,385 |
2023 £ 80,889 (426) 1,066 |
|---|---|---|
| 103,753 | 81,529 | |
| (81,541) | (72,615) | |
| (81,541) | (72,615) | |
| 22,212 99,297 |
8,914 90,383 |
|
| 121,509 | 99,297 |
6 of 15
6078396
Registered Number :
British Society for Histocompatibility and Immunogenetics Statement of Financial Position As at 31 December 2024
| Notes Fixed assets Tangible assets 14 Current assets 15 Debtors Cash at bank and in hand Creditors: amounts falling due within one year 16 Net current assets Total assets less current liabilities Net assets The funds of the charity Unrestricted income funds 17 Total funds |
£ 2024 - |
£ 2023 29 |
|---|---|---|
| - | 29 | |
| 29,305 105,047 |
19,380 88,658 |
|
| 134,352 | 108,038 | |
| (12,843) 121,509 |
(8,770) 99,268 |
|
| 121,509 | 99,297 | |
| 121,509 | 99,297 | |
| 121,509 | 99,297 | |
| 121,509 | 99,297 |
For the year ended 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476,
The trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts. These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies’ regime.
The financial statements were approved and authorised for issue by the Board and signed on its behalf by:
Corinna Freeman Trustee 10 September 2025
7 of 15
British Society for Histocompatibility and Immunogenetics Notes to the Financial Statements
For the year ended 31 December 2024
1. Accounting Policies
Basis of accounting
The financial statements have been prepared under the historical cost convention, except for investments which are included at market value and the revaluation of certain fixed assets and in accordance with the Charities SORP (FRS 102) ‘Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)’, Financial Reporting Standard 102 the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), and the Companies Act 2006.
British Society for Histocompatibility and Immunogenetics meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note(s).
Going concern
During 2024 BSHI was able to continue with its objectives with another successful year of member subscriptions, and the ability to hold the in person annual conference helped to improve income during the year. BSHI continues to seek cost effective ways of supporting their membership and the trustees are confident that BSHI will be able to continue and pursue its objectives for the immediate foreseeable future.
Incoming resources
All incoming resources are included in the statement of financial activities when the Charity is entitled to the income, and the amount can be quantified with reasonable accuracy. The following specific policies are applied to particular categories of income:
Income from investments is included in the year in which it is receivable.
Resources expended
Liabilities are recognised as resources expended when there is a legal or constructive obligation committing the Charity to the expenditure:
Tangible fixed assets
Tangible fixed assets, other than freehold land, are stated at cost or valuation less depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost or valuation of fixed assets, less their estimated residual value, over their expected useful lives on the following basis:
Plant and machinery Computer equipment Motor vehicles Fixtures and fittings
25% Reducing balance 25% Reducing balance 25% Reducing balance 25% Reducing balance
8 of 15
British Society for Histocompatibility and Immunogenetics Notes to the Financial Statements Continued
For the year ended 31 December 2024
3. Income from charitable activities
| Unrestricted funds Charitable activities Advertising Subscriptions Conference Qualifications Other member activities Other member activities Income from charitable activities |
2024 £ 18,500 27,030 3,243 43,735 |
2023 £ 17,850 26,080 2,800 24,045 |
|---|---|---|
| 92,508 225 9,635 |
70,775 - 10,114 |
|
| 9,860 | 10,114 | |
| 102,368 | 80,889 |
4. Income earned from other activities
| Fund raising events nvestment income Unrestricted funds Bank interest receivable Costs of charitable activities by fund type Unrestricted funds Charitable activities Support costs |
2024 £ - |
2023 £ (426) |
|---|---|---|
| - | (426) | |
| 2024 £ 1,385 |
2023 £ 1,066 |
|
| 1,385 | 1,066 | |
| 2024 £ 34,044 47,497 |
2023 £ 25,627 46,988 |
|
| 81,541 | 72,615 |
5. Investment income
6. Costs of charitable activities by fund type
9 of 15
British Society for Histocompatibility and Immunogenetics Notes to the Financial Statements Continued
For the year ended 31 December 2024
7. Costs of charitable activities by activity type
| Support costs Activities undertaken directly £ £ Support costs Charitable activities 47,497 34,044 Analysis of support costs Charitable activities Management Finance Computer costs Depreciation & amortisation EBS Admin charges International Journal of Immunogenetics Print, post & stationery Subscriptions Telephone Governance costs |
2024 £ 81,541 2024 £ 444 1,359 188 29 32,628 6,500 28 - 309 6,012 |
2023 £ 72,615 2023 £ - 1,288 560 10 31,697 6,500 53 580 67 6,233 |
|---|---|---|
| 47,497 | 46,988 |
8. Analysis of support costs
9. Net income/(expenditure) for the year
This is stated after charging/(crediting):
| 2024 | 2023 | |
|---|---|---|
| £ | £ | |
| Depreciation of owned fixed assets | - | 10 |
| Accountancy fees | 1,440 | 1,440 |
| (Gain)/Loss on disposal of intangible fixed assets | 29 | - |
10 of 15
British Society for Histocompatibility and Immunogenetics Notes to the Financial Statements Continued
For the year ended 31 December 2024
10. Particulars of employees
| Employees | 2024 0 |
2023 0 |
|---|---|---|
| 0 | 0 |
12. Comparative for the Statement of Financial Activities
The comparative year values on the Statement of Financial Activities are for unrestricted funds.
13. Intangible fixed assets
| Cost or valuation At 01 January 2024 At 31 December 2024 Amortisation At 01 January 2024 At 31 December 2024 Net book values At 31 December 2024 At 31 December 2023 Tangible fixed assets Cost or valuation At 01 January 2024 Disposals At 31 December 2024 Depreciation At 01 January 2024 Disposals At 31 December 2024 Net book values At 31 December 2024 At 31 December 2023 |
£ Intangible asset 1 6,668 |
|---|---|
| 6,668 | |
| 6,668 | |
| 6,668 | |
| - | |
| - | |
| Plant and machinery £ 380 (380) |
|
| - | |
| 351 (351) |
|
| - | |
| - | |
| 29 |
14. Tangible fixed assets
11 of 15
British Society for Histocompatibility and Immunogenetics Notes to the Financial Statements Continued
For the year ended 31 December 2024
15. Debtors
| Amounts due within one year: Trade debtors Prepayments and accrued income Creditors: amounts falling due within one year Trade creditors Accruals and deferred income |
2024 £ 29,284 21 |
2023 £ 19,380 - |
|---|---|---|
| 29,305 | 19,380 | |
| 2024 £ 11,403 1,440 |
2023 £ 7,330 1,440 |
|
| 12,843 | 8,770 |
16. Creditors: amounts falling due within one year
17. Movement in funds
Unrestricted Funds
| General General Unrestricted Funds - Previous year General General |
Balance at 01/01/2024 £ 99,297 |
Incoming resources £ 103,753 103,753 Incoming resources £ 81,529 81,529 |
Outgoing resources £ (81,541) |
Balance at 31/12/2024 £ 121,509 |
|---|---|---|---|---|
| 99,297 | (81,541) | 121,509 | ||
| Balance at 01/01/2023 £ 90,383 |
Outgoing resources £ (72,615) |
Balance at 31/12/2023 £ 99,297 |
||
| 90,383 | (72,615) | 99,297 |
Purpose of unrestricted Funds
General
Unrestricted funds are funds that can only be used in accordance with the charitable objects and at the discretion of the trustees.
12 of 15
British Society for Histocompatibility and Immunogenetics Notes to the Financial Statements Continued For the year ended 31 December 2024
18. Analysis of net assets between funds
| Analysis of net assets between funds | |
|---|---|
| Unrestricted funds General General Previous year Unrestricted funds General General |
Intangible fixed assets Tangible fixed assets Net current assets / (liabilities) Net Assets £ £ £ £ - - 121,509 121,509 |
| - - 121,509 121,509 |
|
| Intangible fixed assets Tangible fixed assets Net current assets / (liabilities) Net Assets £ £ £ £ - 29 99,268 99,297 |
|
| - 29 99,268 99,297 |
19. Company limited by guarantee
British Society for Histocompatibility and Immunogenetics is a company limited by guarantee and accordingly does not have a share capital.
13 of 15
British Society for Histocompatibility and Immunogenetics Detailed Statement of Financial Activities
For the year ended 31 December 2024
| INCOME AND ENDOWMENT Charitable activities Advertising (Charitable activities) Subscriptions (Charitable activities) Conference (Charitable activities) Qualifications (Charitable activities) Other member activities (Other member activities) Income from charitable activities (Other member activities) Other trading activities Fund raising events Investments Bank interest receivable Total incoming resources EXPENDITURE Charitable activities Cost of direct charitable activity (Charitable activities) SUPPORT COSTS Management Management (Charitable activities) Finance Finance (Charitable activities) Computer costs Computer costs (Charitable activities) Depreciation & amortisation Depreciation & amortisation (Charitable activities) EBS Admin charges EBS Admin charges (Charitable activities) International Journal of Immunogenetics International Journal of Immunogenetics (Charitable activities) |
£ 2024 18,500 27,030 3,243 43,735 225 9,635 102,368 - - 1,385 1,385 |
£ 2023 17,850 26,080 2,800 24,045 - 10,114 |
|---|---|---|
| 80,889 (426) |
||
| (426) 1,066 |
||
| 1,066 | ||
| 103,753 (34,044) (34,044) (444) (444) (1,359) (1,359) (188) (188) (29) (29) (32,628) (32,628) (6,500) |
81,529 (25,627) |
|
| (25,627) - |
||
| - (1,288) |
||
| (1,288) (560) |
||
| (560) (10) |
||
| (10) (31,697) |
||
| (31,697) (6,500) |
14 of 15
This page does not form part of the statutory financial statements
British Society for Histocompatibility and Immunogenetics Detailed Statement of Financial Activities Continued
For the year ended 31 December 2024
| Print, post & stationery Print, post & stationery (Charitable activities) Subscriptions Subscriptions (Charitable activities) Telephone Telephone (Charitable activities) Governance costs Governance costs (Charitable activities) Total resources expended Net Income |
(6,500) (28) (28) - - (309) (309) (6,012) (6,012) |
(6,500) (53) |
|---|---|---|
| (53) (580) |
||
| (580) (67) |
||
| (67) (6,233) |
||
| (6,233) | ||
| (81,541) | (72,615) | |
| 22,212 | 8,914 |
15 of 15 This page does not form part of the statutory financial statements